Halozyme Therapeutics, Inc. Common Stock HALO
i
Market dataready · fetched 2026-11-11T14:54:43.242Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:54:39.022058797Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-11T14:54:42.699447+00:00
Halozyme Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 107.79 | 54.2% | 9.2% | 93.18 | 51.8% | 7.5% |
| 25Δ | 106.30 | 55.2% | 8.0% | 94.36 | 54.7% | 6.7% |
| 30Δ | 104.85 | 56.1% | 6.9% | 95.49 | 54.3% | 5.8% |
| 35Δ | 103.66 | 56.2% | 6.1% | 96.57 | 50.1% | 4.9% |
| 40Δ | 102.47 | 56.2% | 5.4% | 97.65 | 45.9% | 4.0% |
| 45Δ | 101.29 | 56.3% | 4.6% | 98.73 | 41.7% | 3.1% |
| 50Δ | 100.10 | 56.3% | 3.8% | 99.81 | 37.5% | 2.2% |
| 55Δ | 98.95 | 56.4% | 3.3% | 100.82 | 38.1% | 1.9% |
| 60Δ | 97.80 | 56.5% | 2.9% | 101.82 | 39.7% | 1.6% |
| 65Δ | 96.65 | 56.6% | 2.4% | 102.82 | 41.2% | 1.4% |
| 70Δ | 95.50 | 56.7% | 1.9% | 103.82 | 42.8% | 1.1% |
| 75Δ | 93.93 | 58.5% | 1.5% | 104.82 | 44.4% | 0.9% |
| 80Δ | 92.03 | 61.7% | 1.2% | |||
20Δ
- Pseudo strike
- 107.79
- IV
- 54.2%
- B/E move
- 9.2%
- Pseudo strike
- 93.18
- IV
- 51.8%
- B/E move
- 7.5%
25Δ
- Pseudo strike
- 106.30
- IV
- 55.2%
- B/E move
- 8.0%
- Pseudo strike
- 94.36
- IV
- 54.7%
- B/E move
- 6.7%
30Δ
- Pseudo strike
- 104.85
- IV
- 56.1%
- B/E move
- 6.9%
- Pseudo strike
- 95.49
- IV
- 54.3%
- B/E move
- 5.8%
35Δ
- Pseudo strike
- 103.66
- IV
- 56.2%
- B/E move
- 6.1%
- Pseudo strike
- 96.57
- IV
- 50.1%
- B/E move
- 4.9%
40Δ
- Pseudo strike
- 102.47
- IV
- 56.2%
- B/E move
- 5.4%
- Pseudo strike
- 97.65
- IV
- 45.9%
- B/E move
- 4.0%
45Δ
- Pseudo strike
- 101.29
- IV
- 56.3%
- B/E move
- 4.6%
- Pseudo strike
- 98.73
- IV
- 41.7%
- B/E move
- 3.1%
50Δ
- Pseudo strike
- 100.10
- IV
- 56.3%
- B/E move
- 3.8%
- Pseudo strike
- 99.81
- IV
- 37.5%
- B/E move
- 2.2%
55Δ
- Pseudo strike
- 98.95
- IV
- 56.4%
- B/E move
- 3.3%
- Pseudo strike
- 100.82
- IV
- 38.1%
- B/E move
- 1.9%
60Δ
- Pseudo strike
- 97.80
- IV
- 56.5%
- B/E move
- 2.9%
- Pseudo strike
- 101.82
- IV
- 39.7%
- B/E move
- 1.6%
65Δ
- Pseudo strike
- 96.65
- IV
- 56.6%
- B/E move
- 2.4%
- Pseudo strike
- 102.82
- IV
- 41.2%
- B/E move
- 1.4%
70Δ
- Pseudo strike
- 95.50
- IV
- 56.7%
- B/E move
- 1.9%
- Pseudo strike
- 103.82
- IV
- 42.8%
- B/E move
- 1.1%
75Δ
- Pseudo strike
- 93.93
- IV
- 58.5%
- B/E move
- 1.5%
- Pseudo strike
- 104.82
- IV
- 44.4%
- B/E move
- 0.9%
80Δ
- Pseudo strike
- 92.03
- IV
- 61.7%
- B/E move
- 1.2%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 35.04% | |
| 35.08% | |
| 38.30% | |
| 39.15% | |
| 42.07% | |
| 34.85% | |
| 35.18% | |
| 34.42% | |
| 34.42% | |
| 34.38% | |
| 34.69% | |
| 35.22% | |
| 34.61% | |
| 33.16% | |
| 32.32% | |
| 32.23% | |
| 33.81% | |
| 34.68% | |
| 34.10% | |
| 32.71% | |
| 39.08% | |
| 33.95% | |
| 34.04% | |
| 34.65% | |
| 36.13% | |
| 36.04% | |
| 37.42% | |
| 36.66% | |
| 36.18% | |
| 37.95% | |
| 37.24% | |
| 36.91% | |
| 36.01% | |
| 36.63% | |
| 37.76% | |
| 36.69% | |
| 35.74% | |
| 39.95% | |
| 39.82% | |
| 40.36% | |
| 40.74% | |
| 41.75% | |
| 39.89% | |
| 41.06% | |
| 41.34% | |
| 40.19% | |
| 41.69% | |
| 40.45% | |
| 41.36% | |
| 42.19% |
Biotechnology
HELP
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health…
More →HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered…
More →HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is…
More →HUMA
Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels…
More →IBRX
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
More →IDYA
Description unavailable
More →